Active immunization in persons 2-49 yr for the prevention of influenza disease caused by influenza A subtype & type B viruses contained in the vaccine.
Severe hypersensitivity to any component of the vaccine including egg protein, or after a previous dose of any influenza vaccine. Do not administer to childn & adolescents ≤17 yr receiving aspirin or aspirin-containing therapy due to association of Reye's syndrome w/ aspirin & wild-type influenza.
Possible anaphylactic reactions following administration. Increased risk of wheezing following administration in childn <5 yr w/ recurrent wheezing & persons of any age w/ asthma. Carefully consider potential benefits & risks when deciding to administer FluMist Quadrivalent if Guillain-Barré syndrome has occurred w/in 6 wk of any prior influenza vaccination. Persons w/ severe asthma or active wheezing. Immunocompromised persons. Individuals w/ underlying medical conditions that may predispose them to complications following wild-type influenza infection. Not approved for use in childn <2 yr & elderly ≥65 yr.
Reduced effectiveness w/ antiviral drugs that are active against influenza A &/or B viruses if administered w/in 48 hr before or w/in 2 wk after vaccination. Concomitant administration w/ inactivated vaccines; other live vaccines; intranasal products.
Sign Out
